Telesis Bio (NASDAQ:TBIO) Trading Down 1.9% – Should You Sell?

Telesis Bio, Inc. (NASDAQ:TBIO)’s stock price traded down 1.9% during mid-day trading on Thursday . The company traded as low as $2.55 and last traded at $2.55. 5,873 shares traded hands during trading, a decline of 99% from the average session volume of 504,203 shares. The stock had previously closed at $2.60.

Telesis Bio Price Performance

The stock has a 50 day simple moving average of $3.01 and a 200-day simple moving average of $4.15. The firm has a market cap of $4.36 million, a PE ratio of -0.09 and a beta of 1.75.

Telesis Bio (NASDAQ:TBIO) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($7.03) earnings per share for the quarter. Telesis Bio had a negative return on equity of 359.32% and a negative net margin of 282.58%. The business had revenue of $1.55 million during the quarter, compared to analysts’ expectations of $6.50 million.

About Telesis Bio

Telesis Bio, Inc, a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications.